Current Placebo News and Events

Current Placebo News and Events, Placebo News Articles.
Sort By: Most Relevant | Most Viewed
Page 1 of 25 | 1000 Results
Monoclonal antibodies against MERS coronavirus show promise in phase 1 NIH-sponsored trial
A randomized, placebo-controlled Phase 1 clinical trial of two monoclonal antibodies (mAbs) directed against the coronavirus that causes MERS found that they were well tolerated and generally safe when administered simultaneously to healthy adults. The experimental mAbs target the MERS coronavirus (MERS CoV) spike protein used by the virus to attach to and infect target cells. The mAbs were discovered and developed by scientists at the biopharmaceutical company Regeneron. The trial was sponsored by NIAID. (2021-02-23)

Antibody-based COVID-19 treatments work best in concert with immune cells
Antibody-based drugs have been authorized for emergency use in COVID-19 patients by the Food and Drug Administration. Researchers at Washington University School of Medicine in St. Louis have discovered that the ability to interact with other elements of the immune system is an indispensable part of the effectiveness of such antibodies. The findings could help improve the design of the next generation of antibody-based COVID-19 drugs. (2021-02-16)

Existing heart failure drug may treat potential COVID-19 long-hauler symptom
UC San Diego clinical trial suggests ivabradine may be effective in treating postural orthostatic tachycardia syndrome, a potential COVID-19 long-hauler symptom. (2021-02-15)

Regular caffeine consumption affects brain structure
Coffee, cola or an energy drink: caffeine is the world's most widely consumed psychoactive substance. Researchers from the University of Basel have now shown in a study that regular caffeine intake can change the gray matter of the brain. However, the effect appears to be temporary. (2021-02-15)

Peginterferon-lambda shows strong antiviral action to accelerate clearance of COVID-19
A clinical study led by Dr. Jordan Feld, a liver specialist at Toronto Centre for Liver Disease, University Health Network (UHN), showed an experimental antiviral drug can significantly speed up recovery for COVID-19 outpatients - patients who do not need to be hospitalized. This could become an important intervention to treat infected patients and help curb community spread, while COVID-19 vaccines are rolled out this year. (2021-02-05)

The Lancet: Study reports preliminary efficacy and safety results from interim analysis of Russian COVID-19 phase 3 vaccine trial
An interim analysis of data from the phase 3 trial of the COVID-19 vaccine from Russia (Gam-COVID-Vac) suggests that a two-dose regimen of the adenovirus-based vaccine offers 91.6% efficacy against symptomatic COVID-19. The preliminary findings, published in The Lancet, are based on analysis of data from nearly 20,000 participants, three-quarters of whom received the vaccine and one quarter received a placebo. (2021-02-02)

Nivolumab effective treatment for malignant mesothelioma
Nivolumab monotherapy is an effective treatment option for relapsed malignant mesothelioma (MM), according to research presented today at the International Association for the Study of Lung Cancer World Conference on Lung Cancer. (2021-01-30)

Two ADAURA analyses support use of Osimertinib for patients with surgically resected, Stage IB to IIIA non-small cell lung cancer
Two presentations from the ADAURA clinical trial advanced previous research that demonstrated improved disease-fee survival (DFS) outcomes for patients with surgically resected non-small cell lung cancer (NSCLC) receiving osimertinib. The data were reported today at the International Association for the Study of Lung Cancer's 2020 World Conference on Lung Cancer (WCLC) Singapore. (2021-01-29)

Adding ipilimumab to pembrolizumab does not improve efficacy in patients with NSCLC
Adding ipilimumab to pembrolizumab does not improve efficacy and is associated with greater toxicity than pembrolizumab alone as first-line therapy for metastatic non-small cell lung cancer (NSCLC) for patients with a PD-L1 tumor proportion score of greater than or equal to 50% and no targetable EGFR or ALK aberrations. (2021-01-29)

Trying to beat a coke habit with cannabis? Not so fast !
Taking cannabidiol, a chemical in the cannabis sativa plant, isn't an effective way to reduce your dependence on cocaine, researchers at the CHUM Research Centre find. (2021-01-27)

New maintenance treatment for acute myeloid leukemia prolongs the lives of patients
Patients with acute myeloid leukemia (AML), the most common form of acute leukemia in adults, that has gone into remission following initial chemotherapy remain in remission longer and have improved overall survival when they are given a pill form of the cancer drug azacitidine as a maintenance treatment, according to a randomized, international phase 3 clinical trial for which Weill Cornell Medicine and NewYork-Presbyterian are trial sites. (2021-01-22)

Do antidepressants help chronic back pain and osteoarthritis?
Antidepressants are commonly used worldwide to treat pain, however new research from the University of Sydney shows they offer little to no help for people suffering chronic back pain and osteoarthritis and may even cause harm. (2021-01-20)

Antidepressants largely ineffective for back pain and osteoarthritis
Antidepressant drugs are largely ineffective for back and osteoarthritis pain, despite being widely used for these conditions, suggests a review of the evidence published by The BMJ today. (2021-01-20)

Benvitimod cream: a new topical treatment for plaque psoriasis
Psoriasis is a chronic inflammatory skin condition characterized by skin plaques and itching. Currently, the most common topical treatments for psoriasis are corticosteroids and vitamin D3 analogs. But these drugs have various side-effects. A recent phase III clinical trial of the novel non-steroidal compound benvitimod in China, published in Chinese Medical Journal, shows that it is safe and effective and could be a promising new topical treatment for psoriasis. (2021-01-19)

New combination drug therapy offers hope against methamphetamine addiction
A new treatment that combines two existing medications may provide long-sought relief for many battling debilitating methamphetamine use disorder, according to a study to be published tomorrow in The New England Journal of Medicine. (2021-01-14)

New England Journal of Medicine publishes COVID-19 treatment trial results
In a multicenter study funded by the National Institutes of Health, a combination of two drugs, baricitinib and remdesivir, reduced time to recovery in hospitalized COVID-19 patients. The results from sites including UT Health San Antonio and University Health were published Dec. 11 in the New England Journal of Medicine. (2021-01-14)

Medication shows promise for weight loss in patients with obesity, diabetes
A new study confirms that treatment with Bimagrumab, an antibody that blocks activin type II receptors and stimulates skeletal muscle growth, is safe and effective for treating excess adiposity and metabolic disturbances of adult patients with obesity and type 2 diabetes. (2021-01-13)

Antibiotics not needed after most sinus surgeries: randomized controlled trial
Randomized controlled trial comparing antibiotics and placebo after routine endoscopic sinus surgery found no difference in outcomes including infection rates and symptoms. More gastrointestinal side effects were reported in patients taking antibiotics. (2021-01-06)

Beating the bulge with a nice cup of tea
Researchers led by the University of Tsukuba found that healthy volunteers who consumed oolong tea every day had much higher levels of fat breakdown compared with the placebo group, and that the effects were most noticeable during sleep. Importantly, the volunteers developed a tolerance to caffeine over the 2-week study period, with their sleep patterns remaining unaffected by tea or caffeine consumption, indicating that oolong tea may have clinical relevance for weight control. (2021-01-06)

Published data from Moderna COVID-19 vaccine trial show 94.1 percent efficacy
Data from the COVE study, which evaluated mRNA-1273, a vaccine candidate against COVID-19 manufactured by Moderna, Inc., demonstrated 94.1 percent efficacy in preventing symptomatic COVID-19. (2020-12-30)

Results of NIH-sponsored ACTIV-3 trial published
Preliminary results of a Phase 3, randomized, placebo-controlled clinical trial testing the investigative monoclonal antibody LY-CoV555 in hospitalized COVID-19 patients were published today in NEJM. The antibody did not provide clinical benefit compared to placebo. The trial, which had been halted to new enrollment in late October following a recommendation by the independent Data and Safety Monitoring Board (DSMB), is part of the Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV) program. NIAID sponsored the trial. (2020-12-22)

Additional analyses of pridopidine for HD
Positive results from additional analyses of PRIDE-HD and Open-HART trials with pridopidine published in peer-reviewed journal, The Journal of Huntington's Disease. Exploratory additional efficacy data show pridopidine (45 mg bid) to be first drug to exert a significant and clinically meaningful beneficial effect on Total Functional Capacity. Results from Open-HART trial demonstrate potential durability of effect of pridopidine with less TFC decline over 5 years compared to historical placebo group, as well as positive safety and tolerability data. (2020-12-16)

Oral hormone therapy shown to significantly alter metabolome of menopausal women
Groundbreaking research led by a team of scientists including a University of Massachusetts Amherst biostatistician shows that oral hormone therapy (HT) significantly alters the metabolome of postmenopausal women. This finding, which examined blood specimens from the landmark Women's Health Initiative (WHI) study, may help explain the disease risks and protective effects associated with different regimens of hormone therapy. (2020-12-16)

Promising treatment for premenstrual dysphoric disorder, PMDD
The mental symptoms of premenstrual dysphoric disorder improve following treatment with a progesterone receptor modulator, as demonstrated by SciLifeLab researcher Erika Comasco and Professor Inger Sundström-Poromaa, Uppsala University. The mechanism of action of the study drug provides insights into the potential molecular mechanisms underlying this psychiatric disorder and its treatment. (2020-12-10)

Secukinumab in children with plaque psoriasis: Study unsuitable for benefit assessment
Secukinumab in children with plaque psoriasis: study unsuitable for benefit assessment The comparator group was not treated appropriately. Firstly, therapy in this group remained unchanged despite non-response, and secondly, it was continued for longer than approved. (2020-12-04)

Can COVID-19 vaccine trials continue ethically once an efficacious candidate is found?
In a Perspective, David Wendler and colleagues propose guidance on when it can be ethical to continue placebo-controlled COVID-19 vaccine trials after an effective and safe candidate is found - a topic that is particularly relevant given the recent announcements of success in several late-stage clinical trials. (2020-12-03)

β-AR agonist therapy puts the brakes on oral cancer progression
Oral cancer has a high mortality rate that is mainly attributed to metastasis. Researchers from Tokyo Medical and Dental University (TMDU) screened a panel of small chemical compounds for their ability to inhibit metastasis in oral cancer, identifying β2?AR-agonist isoxsuprine as a potential candidate. Treatment of various oral cancer cells with isoxsuprine suppressed their motility, while tumor size was significantly decreased in isoxsuprine-treated mice, suggesting that β-AR-agonist therapy could be an effective new treatment for oral cancer. (2020-12-03)

For teens with migraine, sleeping in (a bit) may help
Research indicates that starting school later in the morning yields health and academic benefits for high schoolers, whose natural body clock tends toward late-to-bed, late-to-rise habits. While parents raise concerns about drowsy driving, irritation and impaired school performance, a new study led by researchers at UC San Francisco suggests another reason to push back the start time. (2020-11-25)

New breakthrough in the treatment of rheumatoid arthritis
People with Rheumatoid Arthritis (RA) could soon benefit from a new drug treatment, otilimab, that not only suppresses inflammation but also significantly reduces patient reported pain scores. (2020-11-25)

Rhythm and bleughs: changes in our stomach's rhythms steer us away from disgusting sights
Does the sight of maggots squirming in rotten food make you look away in disgust? The phrase 'makes my stomach turn' takes on a new meaning today as researchers at the University of Cambridge reveal that changes in the rhythm of our stomachs prompt us to look away from disgusting images. (2020-11-24)

Drug eases recovery for those with severe alcohol withdrawal
Yale scientists say a drug originally developed to treat high blood pressure can reduce severe withdrawal symptoms for patients diagnosed with alcohol use disorder. (2020-11-19)

Vitamin D supplements may reduce risk of developing advanced cancer
In a secondary analysis of VITAL, a team led by investigators at Brigham and Women's Hospital has narrowed in on the connection between taking vitamin D supplements and risk of metastatic or fatal cancer. In a paper published in JAMA Network Open, the team reports that vitamin D was associated with an overall 17 percent risk reduction for advanced cancer. (2020-11-18)

Low levels of choline in pregnant Black American women associated with higher levels of stress
Researchers at the University of Colorado Anschutz Medical Campus have found that many pregnant Black Americans have low levels of choline, an essential nutrient that aids in prenatal brain development. Stress caused by institutional racism may play a role. (2020-11-16)

Trifarotene in moderate acne: No study data for the assessment of the added benefit
Trifarotene in moderate acne: no study data for the assessment of the added benefit. Although acne affects many people and there are treatment alternatives, the new drug was only compared with placebo in the approval studies. (2020-11-16)

Cleveland Clinic led trial shows drug effective in 96% of patients with recurrent pericarditis
Cleveland: Cleveland Clinic researchers leading a global clinical trial have found that rilonacept, an FDA approved drug for other inflammatory diseases, resolved acute pericarditis episodes and reduced risk of pericarditis recurrence. The study was published today in the New England Journal of Medicine and presented at the American Heart Association's Scientific Sessions. (2020-11-16)

Patients taking statins experience similar side effects from dummy pills
People taking dummy pills and statins experienced similar side effects in a new study. (2020-11-15)

Omega-3s did not reduce cardiac events in recent heart attack survivors
Omega-3 supplements in commonly available forms appear to be ineffective in preventing further cardiovascular events among elderly people with recent heart attacks. When compared to a placebo, an omega-3 fatty acids supplement in addition to statin therapy and/or a blood thinner did not reduce the number of cardiac events in a study of more than 1,000 patients in Norway. (2020-11-15)

Side effects often attributed to statins were the same for those taking a placebo
Study participants who reported side effects from cholesterol-lowering medications known as statins also reported the same side effects when they unknowingly took placebo pills. These side effects are real, and it appears may be mostly due to the psychological rather than the pharmacological effects of statins since symptoms were consistent when taking the placebo. (2020-11-15)

Hydroxychloroquine does not help patients hospitalized with COVID-19: Study
Findings from a national study published today in the Journal of the American Medical Association (JAMA) ''do not support'' the use of hydroxychloroquine for the treatment of adult patients hospitalized with COVID-19. (2020-11-13)

The future's uncertain - but noradrenaline can help us adapt
A brain chemical called noradrenaline is responsible for our responses to uncertain situations - helping us to learn quickly and adapt our behaviour, a new study has found. (2020-11-13)

Page 1 of 25 | 1000 Results
   First   Previous   Next      Last   
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.